# Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

> **NCT01529294** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 90 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Iloperidone

## Key facts

- **NCT ID:** NCT01529294
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2013-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01529294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01529294, "Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01529294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*